ALK - THE ALLERGY COMPANY

Pioneering allergy research

Under­standing allergy

ALK has an unrivalled understanding of allergens and how they affect the human body, as well as the link between allergy and respiratory diseases such as asthma.

understanding_allergy

News

  • Post date
    03/12/2018
    Annual General Meeting in ALK-Abelló A/S held on 12 March 2018
  • Post date
    02/21/2018
    New medicine for house dust mite allergic rhinitis and allergic asthma now available in France
  • Post date
    02/16/2018
    ALK’s partner, Torii, gains paediatric approval for the house dust mite SLIT-tablet in Japan
  • Post date
    02/13/2018
    Annual General Meeting in ALK-Abelló A/S on 12 March 2018
  • Post date
    01/30/2018
    Release date of annual report 2017 and audio cast
  • Post date
    01/11/2018
    New Treatment for House Dust Mite (HDM) – Induced Allergic Rhinitis Now Available in US
  • Post date
    12/20/2017
    ALK – Financial calendar for the 2018 financial year
  • Post date
    12/11/2017
    REGISTRATION OF CAPITAL INCREASE OF DKK 92,076 AA SHARES AND DKK 920,760 B SHARES BY THE ISSUE OF NEW SHARES COMPLETED
  • Post date
    12/07/2017
    PRICING AND FURTHER DETAILS ON THE OFFERING OF NEW SHARES IN ALK-ABELLÓ A/S
ALK launches growth strategy
Transformational strategy to redefine ALK's position in the global allergy market and stimulate a new era of growth for the company.
Growth strategy: Establish and succeed in North America
North America is the world's largest allergy market, with over 50 million allergy sufferers, and it offers ALK the greatest medium-term growth potential. For example, there are around 10 million AIT-eligible allergy sufferers in the USA alone, just one-third of whom actually receive AIT today.
Growth strategy: Complete the tablet portfolio for all relevant ages
ALK is committed to offering a full portfolio of tablets for all relevant ages, covering the five most common global respiratory allergies.
Growth strategy: Patient engagement systems and adjacent business
ALK will establish a new commercial consumer care division to drive digital patient engagement with the ultimate aim of creating new value from ALK's expanded allergy presence.

ALK in brief

ALK at a glance
ALK is a research-driven, global pharmaceutical company focusing on allergy prevention, diagnosis and treatment. We are the foremost innovators in allergy immunotherapy – a unique treatment which reduces allergic symptoms and treats the cause of the allergy.
Global presence
ALK employs around 2,300 employees worldwide and has affiliates, production facilities and distributors around the globe. Today, around 1.5 million people worldwide use our products.
ALK's pipeline
Our development programme covers the four most important outdoor allergens in Europe, the USA and Japan (grass, birch and related trees, ragweed and Japanese cedar) and the most important indoor allergen in the world (house dust mites).
ALK's history
ALK has been at the forefront of allergy treatment for almost a century. Our story can be traced back to a small laboratory in Copenhagen, Denmark, in 1923.